Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vertex Pharmaceuticals Inc VRTX

Healthcare Biotechnology
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and... see more

Recent & Breaking News (NDAQ:VRTX)

Vertex Researchers Awarded 2024 Breakthrough Prize in Life Sciences

Business Wire September 14, 2023

Vertex to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference on September 13

Business Wire August 30, 2023

Vertex Appoints E. Morrey Atkinson, Ph.D., to EVP and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations

Business Wire August 29, 2023

Vertex Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine

Business Wire August 3, 2023

Vertex Reports Second Quarter 2023 Financial Results

Business Wire August 1, 2023

European Commission Approves ORKAMBI® (lumacaftor/ivacaftor) for the Treatment of Children With Cystic Fibrosis Ages 1 to <2 Years Old

Business Wire July 5, 2023

Vertex to Announce Second Quarter 2023 Financial Results on August 1

Business Wire June 30, 2023

Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies

Business Wire June 26, 2023

Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions

Business Wire June 23, 2023

Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference

Business Wire June 9, 2023

Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress

Business Wire June 9, 2023

FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Business Wire June 8, 2023

Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 13

Business Wire May 30, 2023

Vertex Announces U.S. FDA Approval for KALYDECO® (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older

Business Wire May 3, 2023

Vertex Reports First Quarter 2023 Financial Results

Business Wire May 1, 2023

Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations

Business Wire April 26, 2023

Vertex to Present at the Bank of America Securities 2023 Health Care Conference on May 9

Business Wire April 25, 2023

Vertex Shareholder Action Reminder

Newsfile April 24, 2023

Vertex Shareholder Action Reminder

Newsfile April 21, 2023

Vertex Shareholder Action Reminder

Newsfile April 19, 2023